Frontiers in Immunology (Jun 2022)

m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment

  • Tingting Zhang,
  • Tingting Zhang,
  • Hengqi Liu,
  • Hengqi Liu,
  • Fenghua Gao,
  • Fenghua Gao,
  • Wenchen Gong,
  • Yaoli Cui,
  • Yaoli Cui,
  • Jin He,
  • Jin He,
  • Lanfang Li,
  • Lanfang Li,
  • Lihua Qiu,
  • Lihua Qiu,
  • Zhengzi Qian,
  • Zhengzi Qian,
  • Shiyong Zhou,
  • Shiyong Zhou,
  • Bin Meng,
  • Xiubao Ren,
  • Huilai Zhang,
  • Huilai Zhang,
  • Xianhuo Wang,
  • Xianhuo Wang

DOI
https://doi.org/10.3389/fimmu.2022.922471
Journal volume & issue
Vol. 13

Abstract

Read online

The role of N6-methyladenosine (m6A) modification in tumor microenvironment has rarely been explored in follicular lymphoma (FL). To examine the role of m6A modification in biological behavior, especially the immune landscape of FL, we utilized the Gene Expression Omnibus database to determine the expression signatures of m6A-regulators by unsupervised clustering, and then condense into a risk score, which was validated in an external cohort from the Tianjin Medical University Cancer Institute and Hospital. Finally, 16 m6A-regulators in 351 FL patients were evaluated and two m6A clusters were identified, characterized by differences in prognosis and biological behaviors. The m6A score was further developed based on 20-genes to quantify the m6A-regulator expression signature in each patient with FL. The low m6A score was associated with inferior prognosis of patients, with a median survival time of 8.84 (95% confidence interval [CI]: 7.251-10.429) years, which was remarkably shorter than that of patients with high m6A scores (15.73 years, 95% CI: 11.729-19.731; p<0.0001). Genes like TNFRSF14, CREBBP, and CARD11 were shown to be more often mutated in the low m6A group. This group was enriched with immune/inflammatory response but along with the abundant infiltration of exhausted T cells and the upregulated PD-1 and PD-L1 expression. Finally, we verified the m6A score could predict the response to anti-PD-L1 antibodies in an immunotherapy cohort. To conclude, the m6A score recognizes a section of FL patients harboring an exhausted tumor microenvironment and may help guide more effective immunotherapy strategies for patients with FL.

Keywords